Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on 24/7 Business Reporter.
Press releases published on March 19, 2025
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
GlobeNewswire
·
March 19, 2025
SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug …
Diamondback Energy, Inc. Schedules First Quarter 2025 Conference Call for May 6, 2025
GlobeNewswire
·
March 19, 2025
MIDLAND, Texas, March 19, 2025 (GLOBE NEWSWIRE) -- Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced that it plans to release first quarter 2025 financial results on May 5, 2025 after the market closes. In connection with the …
Great Southern Bancorp, Inc. announces quarterly dividend of $0.40 per common share
GlobeNewswire
·
March 19, 2025
SPRINGFIELD, Mo., March 19, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Great Southern Bancorp, Inc. (NASDAQ:GSBC), the holding company for Great Southern Bank, declared a $0.40 per common share dividend for the first quarter of the calendar year …
Viper Energy, Inc., a Subsidiary of Diamondback Energy, Inc., Schedules First Quarter 2025 Conference Call for May 6, 2025
GlobeNewswire
·
March 19, 2025
MIDLAND, Texas, March 19, 2025 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”), a subsidiary of Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback”), today announced that it plans to release first quarter 2025 financial results on May 5, …
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 19, 2025
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the …
TWFG Announces Fourth Quarter 2024 and Full Year Results
GlobeNewswire
·
March 19, 2025
– Total Revenues increased 30.8% for the quarter over the prior year period to $51.7 million – – Total Written Premium increased 20.0% for the quarter over the prior year period to $361.4 million – – Organic Revenue Growth Rate* of 20.5% for the quarter – …
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
GlobeNewswire
·
March 19, 2025
SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and …
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 19, 2025
Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique …
Five Below, Inc. Announces Fourth Quarter and Fiscal 2024 Financial Results
GlobeNewswire
·
March 19, 2025
Net Sales Increase of 7.8% for Q4 and 10.4% for Fiscal 2024 ex the 53rd week GAAP Diluted EPS of $3.39 for Q4 and $4.60 for Fiscal 2024 Adjusted Diluted EPS of $3.48 for Q4 and $5.04 for Fiscal 2024 PHILADELPHIA, PA, March 19, 2025 (GLOBE NEWSWIRE) -- Five …
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024
GlobeNewswire
·
March 19, 2025
NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported …
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
GlobeNewswire
·
March 19, 2025
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced it has …
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire
·
March 19, 2025
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an …
Horses.vn Brings the Joy of Horseback Riding to Central Vietnam
EIN Presswire
·
March 19, 2025
DA NANG, HOI AN, VIETNAM, March 19, 2025 /EINPresswire.com/ -- Horses.vn Brings the Joy of Horseback Riding to Central Vietnam Central Vietnam is about to experience a new level of excitement as Horses.vn, founded by Hongly Nguyen and her husband …
AI STARTUP REENA.AI ANNOUNCES FILING OF PATENT FOR REVOLUTIONARY COLLABORATION TECHNOLOGY FOR THE DENTAL INDUSTRY
EIN Presswire
·
March 19, 2025
SCOTTSDALE, AZ, UNITED STATES, March 19, 2025 /EINPresswire.com/ -- Innovative startup reena.ai has filed a patent for its groundbreaking AI-powered communication system designed for the global dental and healthcare industries. The technology, named " …
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
GlobeNewswire
·
March 19, 2025
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for …
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024
GlobeNewswire
·
March 19, 2025
Daix (France), New York City (New York, Etats-Unis), le 19 mars 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par …
MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire
·
March 19, 2025
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …
APP INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AppLovin Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire
·
March 19, 2025
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …
ESTC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elastic N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire
·
March 19, 2025
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz …
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire
·
March 19, 2025
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz …